Factors that influence adherence with disease-modifying therapy in MS

被引:203
|
作者
Treadaway, Katherine [1 ]
Cutter, Gary [2 ]
Salter, Amber [1 ]
Lynch, Sharon [3 ]
Simsarian, James [4 ]
Corboy, John [5 ]
Jeffery, Douglas [6 ]
Cohen, Bruce [7 ]
Mankowski, Ken [8 ,9 ]
Guarnaccia, Joseph [10 ]
Schaeffer, Lawrence [11 ]
Kanter, Roy [12 ]
Brandes, David [13 ]
Kaufman, Charles [14 ]
Duncan, David [15 ]
Marder, Ellen [16 ]
Allen, Arthur [17 ]
Harney, John [18 ]
Cooper, Joanna [19 ]
Woo, Douglas [20 ]
Stuve, Olaf [1 ]
Racke, Michael [21 ]
Frohman, Elliot M. [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75235 USA
[2] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA
[3] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[4] Neurol Associates Fairfax, Fairfax, VA USA
[5] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[6] Wake Forest Univ, Hlth Sci Ctr, Winston Salem, NC 27109 USA
[7] Northwestern Univ, Chicago, IL 60611 USA
[8] MS Inst Inc, Columbus, OH USA
[9] Capital Neurol Serv, Columbus, OH USA
[10] Griffin Hosp, Multiple Sclerosis Treatment Ctr, Derby, CT USA
[11] Neurol Consultants Amarillo, Amarillo, TX USA
[12] VIA Med Ctr, Cheyenne, WA USA
[13] Hope Neurol, Knoxville, TN USA
[14] Louisiana Neurol Consultants, Baton Rouge, LA USA
[15] MKMG Neurol MS Ctr, Mt Kisco, NY USA
[16] Neurol Specialists Dallas, Dallas, TX USA
[17] Neurol Consultants, Overland Pk, KS USA
[18] Dallas Neurol Associates, Richardson, TX USA
[19] E Bay Phys Med Grp, Berkeley, CA USA
[20] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[21] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA
关键词
compliance; adherence; multiple sclerosis; disease; modifying therapy; injections; MULTIPLE-SCLEROSIS; DEPRESSION; MEDICATIONS; ANXIETY;
D O I
10.1007/s00415-009-0096-y
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The complexity and cost of injection treatment can represent a formidable challenge for patients affected by a chronic illness, particularly those whose treatment is primarily preventative and only modestly effective on the more conspicuous symptomatic aspects of the disease process. The aim of this investigation was to identify which factors most influenced nonadherent behavior with the available diseasemodifying injection therapies for multiple sclerosis (MS). A multicenter, observational (threewave) study using surveys was developed and administered to patients with MS through the World Wide Web. Healthcare providers at 17 neurology clinics recruited patients for the study. A total of 798 patients responded to the baseline wave of the study (708 responded to all three waves). The nonadherence rates for all patients (missing one or more injections) across these waves remained relatively stable at 39 %, 37 %, and 36 %, respectively. The most common reason participants listed for missing injections was that they simply forgot to administer the medication (58 %). Other factors including injection-site reactions, quality of life, patients' perceptions on the injectable medications, hope, depression, and support were also assessed in relation to adherence. This study characterizes factors that are associated with failure to fully adhere with disease modifying injection therapy for MS and underscores the principles associated with optimizing adherence and its implications for effective treatment of the disease process in MS.
引用
收藏
页码:568 / 576
页数:9
相关论文
共 50 条
  • [1] Factors that influence adherence with disease-modifying therapy in MS
    Katherine Treadaway
    Gary Cutter
    Amber Salter
    Sharon Lynch
    James Simsarian
    John Corboy
    Douglas Jeffery
    Bruce Cohen
    Ken Mankowski
    Joseph Guarnaccia
    Lawrence Schaeffer
    Roy Kanter
    David Brandes
    Charles Kaufman
    David Duncan
    Ellen Marder
    Arthur Allen
    John Harney
    Joanna Cooper
    Douglas Woo
    Olaf Stüve
    Michael Racke
    Elliot M. Frohman
    Journal of Neurology, 2009, 256 : 568 - 576
  • [2] Factors that influence adherence with disease-modifying therapy in multiple sclerosis
    Treadaway, K
    Hawker, K
    Racke, M
    Brannon, K
    Morrison, A
    Remington, G
    Frohman, E
    Cohen, B
    Corboy, J
    Simsarian, J
    Lynch, S
    Jeffery, D
    MULTIPLE SCLEROSIS, 2005, 11 : S158 - S158
  • [3] Factors that influence adherence with disease-modifying therapy in multiple sclerosis
    Treadaway, KD
    Brannon, KD
    Morrison, A
    Remington, GM
    Olek, M
    Racke, MK
    Frohman, EM
    NEUROLOGY, 2006, 66 (05) : A30 - A30
  • [4] A multivariate analysis of factors that influence adherence with disease-modifying therapy in multiple sclerosis
    Treadaway, Katherine
    Cutter, Gary
    Lynch, Sharon G.
    Corboy, John
    Simsarian, James
    Jeffery, Douglas
    Cohen, Bruce
    Mankowski, Ken
    Guarnaccia, Joseph B.
    Schaeffer, Lawrence
    Brandes, David
    Kaufman, Charles
    Duncan, David
    Marder, Ellen
    Allen, Arthur
    Harney, John
    Cooper, Joanna A.
    Woo, Douglas
    Racke, Michael K.
    Stuve, Olaf
    Kanter, Roy
    Frohman, Elliot
    MULTIPLE SCLEROSIS, 2008, 14 : S182 - S182
  • [5] Factors that influence compliance with disease-modifying therapy
    Treadaway, K
    Hawker, K
    Racke, M
    Brannon, K
    Morrison, A
    Remington, G
    Frohman, E
    JOURNAL OF NEUROLOGY, 2005, 252 : 110 - 111
  • [6] Factors Affecting the Adherence to Disease-Modifying Therapy in Patients With Multiple Sclerosis
    Erbay, Oznur
    Yesilbalkan, Oznur Usta
    Yuceyar, Nur
    JOURNAL OF NEUROSCIENCE NURSING, 2018, 50 (05) : 291 - 297
  • [7] Adherence of Adolescents to Multiple Sclerosis Disease-Modifying Therapy
    Thannhauser, Jennifer E.
    Mah, Jean K.
    Metz, Luanne M.
    PEDIATRIC NEUROLOGY, 2009, 41 (02) : 119 - 123
  • [8] Outcome of MS relapses in the era of disease-modifying therapy
    Muriel Stoppe
    Maria Busch
    Luise Krizek
    Florian Then Bergh
    BMC Neurology, 17
  • [9] Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis
    Schwarz, Carolyn
    Grover, Stephanie
    Powell, Victoria
    Noguera, Austin
    Mah, Jean
    Mar, Soe
    Mednick, Lauren
    Banwell, Brenda
    Alper, Gulay
    Graves, Jennifer
    Lotze, Timothy
    Tillema, Jan-Mendelt
    Rensel, Mary
    Gorman, Mark
    Ness, Jayne
    Waldman, Amy
    Schreiner, Teri
    Waubant, Emmanuelle
    Yeh, E. Ann
    NEUROLOGY, 2017, 88
  • [10] Outcome of MS relapses in the era of disease-modifying therapy
    Stoppe, Muriel
    Busch, Maria
    Krizek, Luise
    Bergh, Florian Then
    BMC NEUROLOGY, 2017, 17